Gene–disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections

S Chinnaswamy

Interferon (IFN) lambda (IFN-λ or type III IFN) gene polymorphisms were discovered in the year 2009 to have a strong association with spontaneous and treatment-induced clearance of hepatitis C virus (HCV) infection in human hosts. This landmark discovery also brought renewed interest in type III IFN biology. After more than half a decade since this discovery, we now have reports that show that genetic association of IFNL gene polymorphisms in humans is not limited only to HCV infections but extends beyond, to include varied diseases such as non-alcoholic fatty liver disease, allergy and several other viral diseases including that caused by the human immunodeficiency virus. Notably, all these conditions have strong involvement of host innate immune responses. After the discovery of a deletion polymorphism that leads to the expression of a functional IFN-λ4 as the prime ‘functional’ variant, the relevance of other polymorphisms regulating the expression of IFN-λ3 is in doubt. Herein, I seek to critically address these issues and review the current literature to provide a framework to help further understanding of IFN-λ biology.

INTRODUCTION

In the year 2003, two different groups reported on the presence of three novel genes closely placed to each other, on human chromosome 19 that coded for interferons (IFNs) with potent antiviral properties.1,2 These genes due to their relatedness to the three novel genes closely placed to each other, on human gastrointestinal and urogenital tracts of mammals.7

The discovery of IFN-λ was seminal in the sense that it showed the presence of an alternate system to the well-known type I IFNs (IFN-α and IFN-β) that the different nucleated cells in the body, especially the ones on epithelial surfaces, can utilize to combat viral infections. Later studies in mice have shown that type III IFNs form a strong barrier at the host–environment interface, which encompasses large regions of epithelial lining to the respiratory, gastrointestinal and urogenital tracts of mammals.7–10

A major boost in the area of IFN-λ research came after another discovery in the year 2009. Three independent groups conducted genome-wide association studies (GWASs) involving treatment response to chronic hepatitis C virus (HCV) infections, in three different geographical regions of the world, and reported that single-nucleotide polymorphisms (SNPs) in the IFNL locus (Figure 1), had strong association with treatment-induced HCV clearance irrespective of ethnicity and geographical location of the hosts.11–13 The search for a ‘causative’ or a ‘functional’ SNP at the IFNL locus that could give a biological explanation for the HCV-GWAS results was taken up vigorously by several groups, but none seem to have given a better explanation to the HCV-IFN-λ ‘puzzle’ than the group from the National Institutes of Health, USA, that discovered the presence of another IFNL upstream to IFNL3, named as IFNL4 (refs 14,15; Figure 1; in Figure 1b, the alleles for the respective SNPs are shown as beneficial (B) or non-beneficial (NB) with respect to the studies on HCV (reviewed in ref. 15; the major allele for each of the SNPs depicted in Figure 1b has been shown to be the beneficial one in HCV infections). Functional IFN-λ4 is expressed only in a subset of individuals, due to a frameshift-causing deletion polymorphism (IFNL4-DG; rs368234815) in the first exon of IFNL4 (Figure 1).14 The presence of the alternate allele (IFNL4-TT) renders IFNL4 a pseudogene and this allele is seen in ~50% of the European population and in most of the east Asian population, but IFNL4 is a functional gene (IFNL4-DG allele) in majority (~95%) of the African population,16 suggesting that human evolution has played an active role in elimination of a functional IFN-λ4 in the human species.17 In fact, the pseudogene shows strong positive selection in human evolution, whereas the functional gene is conserved in other mammalian species except in mice and rats where the gene is completely absent.17

In this article, I review the literature on genetic association studies that have shown the involvement of the HCV-GWAS SNPs in non-HCV disorders that involve both viral diseases and some non-infectious conditions. I also update the progress on transcriptional studies of the IFNL4 gene and examine whether the functional IFN-λ4-generating SNP is sufficient to explain the molecular mechanism of causality in the diseases it is associated with, and whether the other IFNL locus SNPs (mainly the ones

1National Institute of Biomedical Genomics, Kalyani, West Bengal, India and 2Department of Clinical Immunology, Rheumatology and Allergy, Healthy Ageing Research Centre, Medical University of Lodz, Lodz, Poland. Correspondence: Dr S Chinnaswamy, Infectious Disease Genomics, National Institute of Biomedical Genomics, PO. N.S.S., 2nd Floor, Kalyani 741251, West Bengal, India.
E-mail: sc2@nibmg.ac.in
Received 30 January 2016; revised 1 April 2016; accepted 6 May 2016; published online 9 June 2016
regulating IFN-λ3 expression) may have any functional roles to play in the observed phenotypes.

GENETIC ASSOCIATION OF IFNL LOCUS POLYMORPHISMS IS NOT LIMITED TO HCV INFECTIONS: INNATE IMMUNITY IS THE KEY

IFN-L-λs and innate immunity against viruses

Innate and adaptive immunity are the two indispensable arms of the mammalian immune system. Although we had a clearer understanding of the principles of functioning of the adaptive immunity arm, a lack of advanced molecular techniques and incomplete understanding of molecular mechanisms made us remain unaware of the intricacies of functioning of the innate immunity arm, for a long time. With the advent of superior molecular biology techniques and the discovery of the pathogen-associated molecular pattern (PAMP) or pattern recognition receptors, we now have better understanding of how nucleated cells can differentially recognize different classes of pathogens and propagate signals to their surroundings, in the process raising the immediate alarm in the host. Large strides were made in the area of molecular recognition of viral PAMPs and signal transduction that leads to raising of antiviral states within virus-infected cells. The epithelial cells, being at the interface between the host and the environment in the respiratory, gastrointestinal and the urogenital tract, are not only prone to a variety of viral infections but are strategically located to respond and propagate alarm signals to the underlying immune cells (Figure 2). However, the primary function of the epithelium is to provide a physical barrier between the underlying lamina propria and the lumen of the cavity or the exterior. Even though they can sense and respond to PAMPs and damage-associated molecular patterns, the epithelial cells are not professional immune cells and due to their high level of differentiation, may lack the plasticity required to send out amplified and prolonged signals to the lamina propria. Therefore, a crucial link still remained missing about how an adaptive immune response is shaped within distantly located lymph nodes that have obligatory ‘immune-rich environments’, by taking cues from signals generated by viral infections at the epithelium (Figure 2).

The discovery of the new class of effector immune cells called the innate lymphoid cells (ILCs) may seem to have provided the answer to this puzzle (Figure 2). ILCs are derivatives of common lymphoid precursors along with T and B cells. These cells are stationed near the epithelial surfaces in larger numbers and respond to signals from the surrounding cells by secreting cytokines and chemokines in large quantities, thereby acting as signal amplifiers in both health and disease. The ILCs are considered the innate immunity counterparts to the various Th (T helper) cell (CD4+(cluster of differentiation)) subsets of the adaptive immune system (Figure 2; ref. 24). For example, ILC2s respond to IL-33 generated from influenza virus-infected epithelial cells by secreting IL-5 and IL-13, both known inducers of Th2 immunity. The natural killer cells, now classified as ILC1 cells, are considered the Tc (T cytotoxic) cell (CD8+) counterparts. Even though most studies so far on ILCs have been on mice, ILCs have also been characterized in a variety of human tissues and are deregulated in many human diseases. With emerging roles of type III IFNs at the epithelium, and ILCs and IFN-λs now seem to be the major players in innate immunity at barrier surfaces.
How ILCs respond and interact with the epithelial cells during viral infections and how they cross-talk with other immune cells at the barrier surfaces in shaping and maintaining the optimal Th responses, will form the next exciting wave in innate immunity research.

Similarly, research on the production, regulation and functions of IFN-αs in viral infections has also been exciting in the last decade. Human IFN-αs are secreted (except IFN-α4 that is poorly secreted) in response to the detection of viral RNA intermediates from the cytoplasm of epithelial cells via the toll-like receptor and retinoic acid inducible gene I-like receptor pathways. IFN-αs are also known to be secreted by macrophages, plasmacytoid dendritic cells, monocyte-derived dendritic cells and hepatocytes. The IFN-λ1 receptor is expressed on limited cell types including epithelial cells, hepatocytes, B cells and monocytes. There is currently no information on whether the newly discovered ILCs secrete any of the IFN-αs and whether they express IFN-λ1. IFN-αs act in a paracrine and/or autocrine manner to raise an antiviral state in the infected and to-be-infected cells by reprogramming the target cell gene expression patterns. The IFNL SNPs would have functional roles if they can affect the diversification of innate and adaptive immune cell subsets. Diversification of ILC subsets will lead to the polarization of dendritic cells and macrophages and will eventually influence the Th1/Th2 balance by favoring either a Th1 or a Th2 response (Figure 3). Although there is no evidence for this belief, it is known that the IFNL SNPs do affect the expression of IFN-λ3 and that they give rise to a new IFN (IFN-λ4). IFN-λ1, 2 and 3 are known to deflect the Th1/Th2 balance to a Th1 predominant mode in vitro and also in vivo in humans and mice (reviewed in ref. 37). No such studies are reported for IFN-λ4. One hypothesis is that different levels of IFN-λ3 expression dictated by the underlying genetic polymorphisms are responsible for eliciting a Th1 or a Th2 response. The role played by IFN-λ4 in this process is only speculative at this stage (Figure 3). How IFN-λs interact with the newly discovered ILCs is also unknown. A recent report showed that rotavirus infection in mice is controlled by IL-22 produced by ILC3s for which the presence of an intact IFN-λ signaling pathway is required. An even more important question in humans will be on what role does the IFNL SNPs, and therefore IFN-λ4, play in the diversification and functioning of ILCs.

IFN-λ4 apart from being antiviral to HCV is also known to inhibit other flaviviruses such as dengue virus, yellow fever virus and human corona viruses. Some of the other IFN-λs are known to be induced by several human pathogens including M. tuberculosis, human papilloma virus, influenza virus and human metapneumovirus (also induces IFN-λ4), and have clear antiviral activities against some but not other viruses in mice (reviewed in ref. 46). In a recent finding, murine IFN-λ3 but not IFN-α1/IFN-β was responsible for protecting mice against norovirus persistence in mice colon, strikingly, even in the absence of T and B lymphocytes. Similar results were seen in reovirus infections of mice colon. In conclusion, IFN-αs are potent antiviral molecules and their cross-talk with innate immune cells can potentially...
orchestrate innate immunity against several viruses and they may be particularly important at the barrier surfaces. IFN-λs also modulate adaptive immunity by affecting Th1/Th2 balance, tilting it to a Th1-favoring response that is required for clearing viral infections. The function of the newly discovered IFN-λ4 in these immune processes remains to be determined.

Association of IFNL locus polymorphisms with human diseases
In cognizance of the potential that IFN-λs may hold in innate immunity, researchers across the world have got intrigued with the IFNL SNPs and have started to test them in candidate gene case–control studies in both infectious and non-infectious diseases. So far, association has been reported with non-alcoholic fatty liver disease (NAFLD), allergy and infections with several viruses.

Cytomegalovirus. Cytomegalovirus (CMV) is a herpes virus that infects plasmacytoid dendritic cells and epithelial cells in humans causing chronic infections and is especially a problem in immunosuppressed individuals. Egli et al. tested the association of the IFNL SNP rs8099917 with CMV replication in a small number of solid organ transplant patients (n = 38) who were seronegative for CMV (but received an organ transplant from a CMV-seropositive donor) and who had stopped receiving antiviral prophylaxis. They found that the minor allele at rs8099917 (G) was associated with decreased CMV replication (P = 0.036) in a dominant model of inheritance. Further, their in vitro studies provided evidence for a beneficial effect of the minor allele against CMV replication. A study in CMV-seropositive kidney transplant patients also found that the minor allele (T) at rs12979860 had a dominant beneficial effect against CMV replication. Although in another study in allogenic stem cell transplant recipients, the minor allele T at rs12979860 protected recipients against CMV infection in a recessive model of inheritance.

Two more studies have also reported on the association of IFNL SNPs with CMV. The first report by Bibert et al. tested for the occurrence of CMV retinitis among those human immunodeficiency virus (HIV)-infected patients who were at risk of developing CMV retinitis due to low CD4 counts and CMV seropositivity. They found that carriers of two copies of the minor allele (ΔG/ΔG), increased the risk of getting CMV retinitis (P = 0.007) in multivariate regression models. In the second report by Manuel et al., solid organ transplant patients were tested for the association of rs368234815 with cumulative incidence of CMV replication. The results showed that the minor allele homozygotes (ΔG/ΔG), only in the pre-emptive antiviral therapy group but not among those receiving antiviral prophylaxis, had higher incidence of CMV replication. These results are indeed very interesting and sound, but the paradoxical findings of the five groups in terms of the model of inheritance of IFNL SNPs raise some questions. Although two groups showed that their results fit best with a recessive model of inheritance of IFNL SNPs in affecting CMV replication/retinitis wherein minor homozygosity was non-beneficial, the other three studies show an opposite trend where the minor allele had a beneficial effect against CMV replication in both patients and cell culture experiments, involving either dominant or recessive models of inheritance. In stark contrast, a dominant model of inheritance (of the non-beneficial IFNL SNP minor allele) has consistently given the best explanation on the observed phenotypes in association studies with both spontaneous clearance and IFN-based treatment response in chronic HCV.
infections. This discrepancy within the CMV studies may be partly due to statistical fluctuations owing to low sample sizes, and high heterogeneity among patient groups, end points and antiviral regimens that are followed in the different studies. The discrepancy needs be resolved by well-designed replication studies to gain a proper understanding of the role of IFNL SNPs in CMV replication and disease.

**Human T-lymphotrophic virus.** Human T-lymphotrophic virus (HTLV)-1 is an ancient retrovirus causing chronic infections in humans and is associated with adult T-cell leukemia/lymphoma. It is also associated with inflammatory disorders such as HTLV-1-associated myelopathy/tropical spastic paparhesis (HAM/TSP), HTLV-associated arthropathy and several other related disorders including rheumatoid arthritis. A Spanish study reported for the first time that an IFNL SNP (rs12979860) was associated with HAM/TSP in a small number of patients (n=41) who had HTLV-1 proviral DNA in their blood cells. They showed that the presence of the minor allele made 12/41 patients to have a sixfold higher risk (P=0.03) of having symptoms of HAM/TSP compared with asymptomatic carriers (n=29) in a dominant model of inheritance. However, proviral DNA load was a confounder in this association; covariate analysis suggested that both the SNP and proviral DNA load were linked in their association with HAM/TSP. The minor allele-carrying genotypes (CT and TT) were indeed having higher proviral DNA in their blood cells compared with the major homozygotes (P=0.01). The major drawback of this study seems to be the low sample number; although the strength of the study was that there was significant effect of the minor allele on proviral DNA copy number, a functional association that could be directly linked with the antiviral role of IFN-λ3. It is known that the IFNL SNP minor alleles are associated with decreased expression of IFN-λ3 (reviewed in ref. 15, although an opposite effect is evident in chronic HCV infections, where the minor allele carriers have low baseline virus levels). In a later study from Brazil, both rs8099917 and rs12979860 were tested in a cohort consisting of 229 HTLV-positive subjects (93 HAM/TSP patient and 136 asymptomatic carriers). The minor allele G of rs8099917 was significantly associated with HAM/TSP in both univariate and multivariate analysis with a recessive model of inheritance (P<0.001). In this study, the proviral DNA load as a covariate did not seem to interfere with the association of rs8099917 with HAM/TSP unlike the previous Spanish study. With respect to rs12979860, the minor allele T was associated with HAM/TSP only as a heterozygote in univariate analysis (P=0.01) and weakly in multivariate analysis (P=0.06).

However, a series of studies have also reported conflicting results to the above two reports on the association of IFNL SNPs with HTLV-1-associated diseases. First, Sanabani et al. show clearly a lack of association of IFNL SNP rs12979860 with HAM/TSP and/or adult T-cell leukaemia/lymphoma. This Brazilian study had more number of samples (n=112) than the Spanish study of Trevino et al. (n=41). They also did not find any correlation of proviral DNA load with rs12979860 genotypes. Another report from Brazil with a sample size of 79 also reflected similar findings, where they found no association of rs12979860 with HAM/TSP and proviral DNA load. This study also compared 300 healthy controls with 79 HTLV-1-positive subjects and found no association with rs12979860 and HTLV-1 infection. Yet another recent study from Brazil analyzed the genotypes at rs8099917, rs12979860 and rs8103142 in 300 healthy controls and 96 HTLV-1-infected individuals, and found no association with HTLV-associated arthropathy and any of the three SNPs when tested individually. When they carried out haplotype analysis, they found some association (P=0.01) with HTLV-1 infection and one of the seven haplotypes (CCT) involving the three SNPs (rs8099917, rs12979860 and rs8103142); with HTLV-associated arthropathy and another haplotype (TTG; P=0.05). They also found an association of the three SNPs individually with levels of some cytokines (such as IFN-γ) and proviral DNA load (P<0.05). However, no multiple testing corrections seem to have been carried out in their analysis, thus severely undermining the results. Further, a Japanese study also failed to see any association with adult T-cell leukemia/lymphoma and rs8099917 and also with HTLV-1 and HCV mono- or co-infections. Last, a study from France on 95 HTLV-1-positive subjects of Afro-Carribean lineage compared the distribution of genotypes of rs12979860 and the IFN-λ4-generating SNP rs368234815, and found no association with HAM/TSP. In summary, the results so far are not entirely convincing on a true association of the IFNL SNPs with HTLV infection-related diseases. Further, in the two reports that did see an association, the models of inheritance used to fit the phenotype data do not agree with each other, raising doubts on the underlying functionality of the observed genetic associations. Therefore, more functional characterization of the observed association may be needed to rule out false positivity.

**Hepatitis B virus.** If at all there is another human disease where IFNL SNPs were expected to have associations as strong as that of HCV infections, it was the case of hepatitis B virus (HBV). This expectation is because both viruses are hepatotropic and cause chronic infections; both diseases can be effectively treated using IFN-α even though they differ in their PAMP ligands recognized by innate immune receptors. Mixed results have been obtained about the role of IFNL SNPs in both spontaneous clearance and IFN-α-induced clearance of HBV and the literature until the year 2013–2014 has been reviewed elsewhere. Although consistent results were obtained across numerous studies with HCV–IFNL SNP association mainly because they had only virological end point phenotypes that correlated well with serological and biochemical parameters of the infection, several drawbacks in case of HBV studies may be responsible for the inconsistent results. Some of them are: presence of different HBV genotypes as mixed infections, with some genotypes (genotype D) showing better association than others; variation in treatment regimens (IFN alone or with nucleotide analogs); end point phenotypes varying from serology to viral load, to biochemical parameters without a common quantitative parameter to assess the phenotype; prolonged clinical course of the disease with fluctuating virological, serological and biochemical markers; and prevalence rates of disease differing in different ethnicities/populations, to name a few. The reports that have shown an association of IFNL SNPs with HBV spontaneous or treatment-induced clearance are largely in agreement with the results from HCV studies in terms of the model of inheritance (Supplementary Table 1). Although the conflicting data so far on HBV–IFNL SNP association do lead to doubts about its true positive nature, the data are also not fully supportive of the notion that the association may be false positive. In fact it has been argued that if properly assessed, the association between HBV disease progression and IFNL SNPs could have clinical value. But it appears that the effect of the IFNL SNPs on HBV persistence and/or progression within the human host is highly variable; it may involve more complex interactions with other variables and genes than was observed in chronic HCV infections.

**Human immunodeficiency virus.** Another important viral disease that has been tested for the influence of IFNL SNPs is acquired
imunodeficiency syndrome (AIDS) caused by HIV. Particularly, it was of interest to see how the IFNL SNP beneficial alleles are distributed in a unique group of HIV-infected individuals that can suppress the virus from replicating to high levels (defined as elite controllers/suppressors or natural viral suppressors) and defer the progression to AIDS (called as long-term non-progressors) without any antiretroviral therapy; and another unique group that remains HIV-seronegative despite being at high risk for infection due to intravenous drug use (highly exposed seronegative or exposed seronegative). More interestingly, the natural viral suppressor patients have also been known to efficiently clear HCV in HCV-HIV co-infections, compared with controls in both African Americans and Caucasians.87 A few reports have come up in this area, some showing no correlation of HIV infection/disease progression to the IFNL SNPs, whereas others see clear association.88–74 One of the earlier reports tested the association of rs12979860 in 291 high-risk seronegative and 1221 HIV-positive subjects comprising both white and black subjects in the USA.88 No association was evident for either HIV positivity or for disease progression within the infected subjects. In another study reported by Rollon et al.,69 the association of rs12979860 was tested in two different cohorts. The first comprised of 30 long-term non-progressors and 38 typical progressors to AIDS; the second included 29 exposed seronegative and 29 HIV-positive partners. Thus, the study tested both HIV progression and protection, although in a small number of patients. No significant difference in distribution of genotypes between cases and controls was evident in both cohorts, although the beneficial CC genotype was more frequent in the exposed seronegative patients compared with HIV-positive patients (62% vs 45%), suggesting that there may be a protective role for the CC genotype against HIV that was not detected in the study, likely due to inadequate power. Another study from the USA tested whether the beneficial CC genotype at rs12979860 was over-represented in 25 African-American elite controllers/suppressors compared with HIV-infected patients with high viral loads, and found no statistically significant difference.70 Confirming this report, Sajadi et al.71 also found that CC genotype (for rs12979860) was not significantly over-represented in 48 natural viral suppressors of African-American origin compared with HIV-positive (n = 124) and -negative controls (n = 173). Three reports published subsequently have seen association with rs12979860 and rs368234815, and spontaneous control of HIV and the progression.72–74 Interestingly, a recent study were carried out on whites/Caucasians, whereas the reports that failed to see an association described above were mostly carried out on African Americans (except that by Rollon et al.69 that used white subjects) or mixed group of blacks and whites.88 First, Machmach et al.72 found an association of rs12979860 with spontaneous HIV control when tested on 53 white natural viral suppressors and 389 matched non-controllers at P = 0.02 after correcting for occurrence of HLA-B57 (human leukocyte antigen) protective alleles (which also have independent association with HIV and HCV spontaneous clearance) and gender, in multivariate analysis. Second, Machmach et al.73 confirmed and extended their results in another report, where they found the association of rs368234815 with AIDS progression. Last, a recent study carried out on a well-characterized Spanish white cohort of HCV-seropositive men exposed to HIV infection through shared needles shows a clear association of IFN-x4-generating rs368234815 with HIV positivity.74 The study had 213 men who were HIV seropositive and 188 were highly exposed seronegative. They found that the protective TT/TT genotype was over-represented in the highly exposed seronegative group (0.49 vs 0.41; P = 0.006). Further, this association had no interaction with the HIV-protective CCR5 (C–C chemokine receptor type 5) deletion (P = 0.7). Interestingly, all three studies that found an association show data that the non-beneficial minor alleles are following a recessive model of inheritance,72–74 suggesting a common underlying functionality in the observed genetic association between the three studies. This is however different from the dominant model of inheritance seen in HCV studies,11–13,15 suggesting that the two viruses may have different interactions with IFN-x-driven immune responses. However, unlike in the case of CMV studies discussed above,47–51 all three HIV studies72–74 show that the minor alleles are non-beneficial, similar to the observations in chronic HCV infections.15 In summary, it is evident that IFNL SNPs do associate with HIV replication and disease progression, even though in an ethnicity-specific manner. It appears that the beneficial alleles of IFNL SNPs have protective roles in whites/Caucasians. In African Americans, more studies with the functional IFN-x4-generating SNP rs368234815 rather than rs12979860 will reveal any true association. This is especially true as the two SNPs are not in strong linkage disequilibrium (LD) in this population (Figure 1b).

Herpes simplex virus. Herpes simplex virus resides inside the human host latently in sensory neurons, but gets reactivated due to the altered host immunity and replicates efficiently in epithelial cells causing genital or oral lesions (the latter is referred to as ‘cold sores’). An association of rs12979860 with the recurrence and severity of herpes simplex virus-1-induced ‘cold sores’ was reported from a study on a small number of individuals (n = 57).75 A recent report carried out on a large number of individuals (n = 2192 for genital herpes; n = 1511 for oral herpes) clearly found no association of rs368234815 with recurrence of genital or oral herpes episodes.76 Among other phenotypes, the latter report ruled out an effect of the SNP on ‘frequency of recurrence’ of oral herpes, it however did not rule out an effect of the SNP on severity of infection.

Non-infectious diseases and miscellaneous conditions. IFNL SNPs have also been tried as candidate gene SNPs in some non-infectious inflammatory diseases. The association of IFNL SNPs with NAFLD was earlier reported by Petta et al.77 This study with 160 subjects identified an independent association with the CC genotype at rs12979860 and the severity of lobular inflammation (CC genotype positively correlated with severity of inflammation) in a cohort of patients with NAFLD (P < 0.001). The study was conducted taking lead from previous reports of increased hepatic necroinflammation in HCV patients with the CC genotype at rs12979860.78 Another report showed no such association in 195 Caucasian biopsy-confirmed NAFLD patients.79 However, all the patients in this cohort were obese (with body mass index > 30), whereas in the previous study only 40% were obese. After the latter report, Petta et al.80 revisited their data and indeed found an association with the IFNL SNP only with their non-obese patients (n = 94; P = 0 < 0.001) but not with the obese patients (n = 66; P = 0.13). These initial doubts seem to have been resolved with a recent report by Eslam et al.81 who worked on a relatively large number of NAFLD patients (n = 488) and confirmed the association of the CC genotype at rs12979860 with increased severity of liver inflammation and fibrosis (P = < 0.0001). They also found a similar strong association with hepatic inflammation and fibrosis in separate cohorts of viral hepatitis C (n = 3129) and B (n = 555), strongly suggesting that even though the major allele genotype CC is beneficial against HCV and HBV, it is also responsible for excess inflammation of the liver in viral and non-viral hepatitis. All four studies77–81 report on dominant models of inheritance for the minor alleles; but unlike in the context of chronic HCV infections,11–13 the minor alleles in NAFLD are beneficial rather than being non-beneficial, as they are responsible for less severe hepatic inflammation.

Extending the potential role for IFNL SNPs in inflammatory diseases, there is also a recent report that showed association of rs12979860 and allergy in children aged < 5 years.82 Although the
The study involved a small sample size (non-allergic, n = 35; allergic cohort 1, n = 35; food allergy cohort 2, n = 30), a large effect size (odds ratio = 4.56, P = 0.004, for cohort 1) was seen wherein the non-beneficial T allele at rs12979860 was over-represented in the allergy group in a dominant model of inheritance. Another interesting finding in this study was that the effect of the IFNL SNP was more pronounced in females than males. This report suggests that the non-beneficial IFNL SNP minor allele-carrying genotypes may predispose children to an allergic phenotype by skewing the Th1/Th2 balance to a Th2 predominant one. This extrapolation is based on the Th1/Th2 balance to a Th2 predominant one. This extrapolation is also based on the findings from a recent study on mice model of allergic asthma, which showed that IFN-α2 was able to rescue mice from allergy by suppressing Th2 cytokines.39 These conclusions would also suggest a role for IFNL SNPs in immune response to respiratory viral infections, which account for disease exacerbations in conditions such as asthma.83 A study carried out on infants with respiratory syncytial virus-induced bronchiolitis shows no association of r12979860 and rs8099917 with viral load or other clinical features.84 Interestingly, the non-beneficial TT genotype of rs12979860 was associated with early age of hospitalization in the infants (P = 0.005). More studies are awaited on the association of IFNL SNPs with allergy and allergy-related diseases. In the autoimmune disorder multiple sclerosis, rs8099917 and rs12979860 did not show any association with IFN-β treatment.85

As evidence for a potential role of IFN-αs and IFNL SNPs in adaptive immune responses, a study has linked IFNL SNPs with development of effective vaccine response against human influenza virus in immunosuppressed individuals.86 The study shows that minor allele (G)-carrying individuals at rs8099917 show better vaccine responses (odds ratio = 1.99; P = 0.038) in a dominant model of inheritance, and that T cells from minor allele-carrying individuals produce more IL-4 (a Th2 cytokine). This study also showed that recombinant IFN-α3 increased Th1 responses from human peripheral blood mononuclear cells while inhibiting Th2 responses (Th2 cytokines are needed for effective seroconversion).86

**TRANSCRIPTION STUDIES ON THE IFNL4 GENE**

Studies have accumulated evidence on the different transcription factors (TFs) that bind and drive transcription from all four IFNL genes. Roles for several virus-inducible TFs such as NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), IFN regulatory factor-3 and IFN regulatory factor-7 have been defined for IFNL1, 2 and 3 genes, and have been reviewed elsewhere.28,87,88 We recently showed that apart from these three TFs, specificity protein 1 (a GC-rich DNA-binding TF) also has a role in driving transcription from the IFNL4 promoter in A549 cells89 (Figure 4a). A CpG island of ~ 1.5 kb is located upstream of the IFNL3 gene and overlapping the IFNL4 gene, and also includes two of the most important IFNL SNPs rs12979860 and rs368234815. Epigenetic regulation of the transcriptional activity at the IFNL locus is likely to involve this CpG island and needs further exploration.90,91

Even though IFNL4 messenger RNA (mRNA) was shown to be highly expressed from stimulated primary hepatocytes in the original report that described the discovery of IFNL4,92 subsequent studies have not seen robust expression levels of IFNL4 gene in human samples. For example, Amanzada and others found IFNL4 transcripts expressed at 4.3–5.6-fold lower levels than IFNL2/3 mRNA in liver biopsies of HCV-infected patients.92 In another report, IFNL4 mRNA was detectable in only 7/23 and 8/23 patient-derived peripheral blood mononuclear cells that were stimulated or not with IFN-poly(I:C), respectively.93 All 23 patients carried at least one copy of the functional IFNL4-generating allele, ΔG. In the report by Liang and colleagues also, IFNL4 transcripts were seen in only 33/70 liver biopsies from HCV-infected patients.94 Furthermore, Lu et al.95 found that only 2% of the transcripts generated from poly(I:C)-stimulated primary hepatocytes derived from two heterozygous (TT/ΔG) at rs368234815 individuals, represented functional IFNL4 transcripts that originated from the ΔG allele. Similarly, they also found no expression of the full-length functional IFNL4 mRNA transcripts from poly(I: C)-stimulated A549 cells. It is possible that the qPCR assays utilized in these studies may be suffering from technical difficulties in dealing with several different mRNA isoforms of IFNL4 gene.14 All the four studies described above have used primer sets where at least one of the primers binds to the exon/intron/exon–intron junctions (Figure 4b). Using a primer set that uniquely binds to the 3’-untranslated region of IFNL4 mRNA, IFNL4 induction was seen at levels similar to that of IFN-α2/3, upon human metapneumovirus infection of A549 cells by Banos-Lara et al.96 We used the same primer set and found similar high expression levels upon poly(I:C)/HCV RNA transfection in A549 cells97. Two other studies have reported no such problems in amplifying IFNL4 transcripts.
from liver biopsies. Although Honda et al. used the allele-specific Taqman assay described earlier, Konishi et al. do not provide the primer sequence information that they used in their Taqman assays. The inconsistency in the above reports in detection of IFNL4 transcripts (either the full-length functional IFN-λ4 isoform or the other isoforms) suggests that RNA-sequencing may be the optimal approach to measure IFN-λ4 transcripts. Furthermore, the pre-mRNA splicing mechanism that leads to the expression of different IFN-λ4 isoforms under different stimulation and cell-type conditions needs to be examined.

THE RELEVANCE OF OTHER ‘IFN-λ3 FUNCTIONAL SNPS’ AFTER THE DISCOVERY OF FUNCTIONAL IFN-λ4-GENERATING SNP

Till date, three functional SNPs have been identified that regulate IFNL3 gene transcription/translation (referred to as ‘IFN-λ3 functional SNPs’ in this section). Although rs28416813 is a SNP present at ~37 nucleotides upstream of the start codon of IFNL3 and is known to affect downstream gene expression by differentially binding to NF-κB, they predicted to be two of the four potential causal SNPs from among the HCV-GWS hits. A recent study defines another mechanism by which rs4083217 affects the stability of RNA by remodeling its secondary structure. Furthermore, a third functional SNP is the TA repeat polymorphism rs59702201, originally reported by the Mizokami group. This SNP located within the proximal promoter affects transcription of IFNL3, depending on the number of repeats present. Recent reports have confirmed the significance of this SNP in association studies involving chronic HCV infections. Apart from several reports that showed genotype-dependent differences in expression levels of IFN-λ3 (reviewed in ref. 15) recent reports also have confirmed this finding in ex vivo and in vivo conditions. These results suggest that IFN-λ3 expression levels dictated by the alleles present at the three functional SNPs may have a role in the observed phenotype in health and disease.

However, the discovery of the IFN-λ4-generating SNP (rs368234815, referred to as ‘IFN-λ4 functional SNP’ in this section) has overshadowed the importance of the ‘IFN-λ3 functional SNPs’, as most of the new reports have chosen to test for the ‘IFN-λ4 functional SNP’ rather than rs12979860, which is the tag-SNP for the ‘IFN-λ3 functional SNPs’. Another SNP within the coding region of IFNL4 that leads to a non-synonymous mutation in the functional IFN-λ4 protein is thought to be a better marker of association along with rs368234815, in chronic HCV infections. So the question arises: is the IFN-λ4-generating SNP the sole functional SNP or the other SNPs regulating the expression of IFN-λ3 also have independent roles? The answer to this question will be difficult to obtain under in vivo conditions due to high LD between these SNPs in most populations that precludes any attempts to assess their independent effects (Figure 1b). A recent report compared the strength of association of rs4083217 and rs368234815 in IFN treatment response in HCV-infected African Americans, who have the lowest reported LD values among all ethnicities between rs368234815 and rs12979860 SNPs (Figure 1b). They found that rs368234815 was more strongly associated with the outcome than rs4083217. In another independent report, Lu et al. applied multivariate regression to test the independence of rs368234815 from rs4083217 in predicting response to IFN treatment in HCV patients of African-American decent. They found that correcting for the effect of rs368234815 on rs4083217 abolished the latter SNP’s association with treatment response, whereas correcting for the effect of the latter SNP reduced the strength of association of the former SNP (from $P=0.004$ to 0.065). This could have resulted due to the low sample size ($n=169$); nevertheless, more results are awaited to conclude that IFN-λ4-generating SNP is the sole functional SNP and that the observations giving credence to the functionality of the other ‘IFN-λ3 functional SNPs may only be artifacts.

Studies so far point to the functional IFN-λ4-generating SNP rs368234815 as the prime causal variant at the human IFNL locus. Therefore, a detailed investigation is needed on the function of IFN-λ4 as both an antiviral cytokine in different viral diseases and as a potential player in diversification and maintenance of innate and adaptive immune cell subsets. In case of IFN treatment response in chronic HCV infections, even though the IFN-λ4-generating SNP can explain a large amount of variance in the observed phenotypes, questions still remain on its role in spontaneous clearance of HCV. It is known that expression of functional IFN-λ4 is associated with high levels of IFN-stimulated gene (ISG) expression in non-responders who further fail to upregulate their ISG expression upon IFN-α treatment. However, such an elegant explanation is lacking in the case of spontaneous clearance of HCV (Figure 5). Although the majority of studies on spontaneous HCV clearance are with rs12979860 and not rs368234815, the fact that these two SNPs are in high LD in most populations allows us to extrapolate the results. So, how does the expression of a functional IFN-λ4 in patients who get an acute HCV infection will lead them to become chronically infected? One explanation could be that similar to the IFN treatment non-responders group, the subjects expressing functional IFN-λ4 also have higher baseline levels of ISGs, which do not get further upregulated upon acute HCV infection. Having a higher basal innate immune response may have helped those populations with higher frequency of the functional IFN-λ4-generating allele in dealing with prevalent viral infections. Higher baseline levels of ISGs in people who can express a functional IFN-λ4 may be offering protection against excess inflammation of the liver in hepatitis of non-viral origin such as NAFLD. As evident from studies on spontaneous and treatment-induced clearance of HCV, such a pre-emptive state may become non-beneficial in dealing with hepatitis of viral origin. Further, there may be other conditions that we do not yet know in which expression of a functional IFN-λ4 may be beneficial. Therefore, an epidemiological investigation to assess basal ISG expression levels, in humans both in health and disease, and their correlation with expression of IFN-λ4, is needed. Further, studies are also needed to examine why hepatic IFN-λ3 levels are lower in the beneficial allele/genotype-carrying individuals during chronic HCV infection and how this phenomenon is reversed once treatment is initiated (Figure 5c; ref. 94).

Although IFN-λ1, 2 and 3 are known to associate with a Th1 response, no information is available in this regard for IFN-λ4. If the hypothesis that higher levels of IFN-λ3 expression (due to presence of major alleles) will lead to a Th1 predominant response is to be believed, then by extrapolation, IFN-λ4 should promote Th2 responses (Figure 3; as ‘IFN-λ3 functional SNPs’ and ‘IFN-λ4 functional SNP’ are in strong LD and the minor allele will give rise to IFN-λ4). This explanation is difficult to reconcile with the observations that IFN-λ4, except for being a poorly secreted IFN, requires the same dimeric receptor for signaling and can stimulate not only similar set of ISGs but also at similar levels when compared with IFN-λ3. Besides, both IFN-λ4 and IFN-λ3 have similar antiviral potencies in vitro. Therefore, expression of IFN-λ4 and its associated ISGs in a subset of individuals carrying minor alleles is less likely to favor a completely opposite phenotype to that seen in those carrying major alleles that induce higher levels of IFN-λ3 expression.

CONCLUSIONS

Human IFNL SNPs came to the limelight after genetic studies showed their relevance in chronic HCV infections in the year 2009.
SNPs may involve interactions with variables other than just standard end point phenotypes in many of the reported diseases/conditions. Therefore, future studies should aim at dissecting these interactions to arrive at meaningful results. Well-designed replication studies and functional studies to strengthen the genetic association results are required to arrive at firm conclusions. Importantly, IFN-λ4 has emerged as the key causal link to the genetic associations, but many questions remain on its functional role in the diversification and shaping of innate and adaptive immune responses in viral infections and other inflammatory conditions.

CONFLICT OF INTEREST

The author declare no conflict of interest.

ACKNOWLEDGEMENTS

The author dedicates this article to Professor Partha P. Majumder, Director, National Institute of Biomedical Genomics, Kalyani, India, on a successful journey in nurturing human genetics research in India. The author was (partially) supported as a visiting scientist by the Healthy Ageing Research Centre (HARC) project (REGPOT-2012-2013-1, 7FP). The author thanks Professor Marek L. Kowalski, Chair, Department of Immunology, Rheumatology and Allergy and Director, HARC, Medical University of Lodz, Poland, for his support and critical comments on the manuscript. The author also thanks Anand Bhusan and Sumona Ghosh for help in preparing the Figures and Supplementary Table 2. The funding for this work was provided by NIBMG, India and HARC, Poland.

REFERENCES

1. Kotenka SV, Gallagher G, Baurin VW, Lewis-Antes A, Shen M, Shah NK et al. IFN-lambda mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2002; 4: 69–77.
2. Sheppard P, Kinds vogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE et al. IL-28, IL-29 and their class II cytokine receptor IL-28 R. Nat Immunol 2002; 4: 63–68.
3. Witte K, Witte E, Sabat R, Walk K. IL-28A, IL-28B, and IL-29: promising cytokines with type 1 interferon-like properties. Cytokine Growth Factor Rev 2010; 21: 237–251.
4. Coccia EM, Severe M, Giaconini E, E, Monneron D, Remoli ME, Julkunen I et al. Viral infection and Toll like receptor agonists induce a differential expression of type I and II interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796–805.
5. Sommeregns C, Paul S, Staelhepi P, Michiels T. IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4: e1000017.
6. Minh S, Frese M, Meier V, Wietzke-Braun P, Scharf J-G, Bartenschlager R et al. Interferon type I gene expression in chronic hepatitis C. Lab Invest 2004; 84: 1148–1159.
7. Ank N, Iversen MB, Bartholdy C, Staelhepi P, Hartmann R, Jensen UB et al. An important role for type III interferon (IFN-lambda/IL-28) in TRM-induced antiviral activity. J Immunol 2008; 180: 2474–2485.
8. Mahlikov T, Landezep H, Gronke K, Diefenbach A, Staelhepi P. Leukocyte-derived IFN-κR and epithelial IFN-λ1 constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog 2015; 11: e1004782.
9. Nice TJ, Baldrige MT, McCune BT, Norman JM, Lazear HM, Artymov M et al. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science 2015; 347: 269–273.
10. Wack A, Terczyńska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol 2015; 16: 802–809.
11. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.
12. Suppiah V, Moldovan M, Ahenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100–1104.
13. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105–1109.
14. Prokunina-olsson L, Muchmore B, Tang W, Pfeffer RM, Park H, Dickensheets H et al. A variant of the interleukin-12 (IL28B) creating a new interferon gene IFNL4 is...
associated with impaired clearance of hepatitis C virus. Nature 2013; 435: 164–171.

Chinnaswamy S. Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions. J Interferon Cytokine Res 2014; 34: 479–497.

O'Brien TR, Prokunina-Olsson L, Dannaley RP. IFN-λ: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res 2014; 34: 829–838.

Key FM, Peter B, Dennis MY, Huerta-Sánchez E, Tang W, Prokunina-Olsson L et al. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of the interferon lambda 4 (IFNL4). PLoS Genet 2014; 10: e1004681.

Beutler B. Innate immunity: an overview. Mol Immunol 2004; 40: 845–859.

Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2002; 22: 240–273.

Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009; 227: 75–86.

Peterson LW, Arts D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 2014; 14: 141–153.

Sonnenberg GF, Artis D. Innate lymphoid cells in the initiation, regulation and suppression of inflammatory responses. J Interferon Cytokine Res 2016; 40: 632–635.

Jackson DJ, Makrisioti H, Rana BM, Shanji BW, Trujillo-Torrallo MB, Foutt J et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med 2014; 190: 1373–1382.

Hazenberg MD, Spits H. Human innate lymphoid cells. Blood 2014; 124: 700–709.

Hepworth MR, Sonnenberg GF. Regulation of the adaptive immune system by innate lymphoid cells. Curr Opin Immunol 2014; 27: 75–82.

Laaree HM, Nice TJ, Diamond MS. Interferon-α: Immune functions at barrier surfaces and beyond. Immunol 2015; 43: 15–28.

Wojno EDT, Artis D. Innate lymphoid cells: balancing immunity, inflammation and tissue repair in the intestine. Cell Host Microbe 2012; 12: 445–457.

Hamming OJ, Terzyczyńska-Dyla E, Vieyres G, Dijkman R, Jorgensen SE, Akhtar H. Interferon lambda 4 signals via the IFNA receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 2013; 32: 3055–3065.

Crotta S, Davidson S, Mahalković T, Desmet CJ, Buckwalter MR, Albert M et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog 2013; 9: e1003773.

Siren J, Pihonen J, Jullkunen I, Mattikanen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28 and IL-29. J Immunol 2005; 174: 1922–1937.

Yin Z, Dai J, Deng J, Sheik H, Natalia M, Shih T et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol 2012; 189: 2735–2745.

Hillyer P, Mane VP, Schramm LM, Puig M, Verthelyi D, Chen A et al. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol 2012; 90: 774–783.

Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Steery W et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009; 10: 702–714.

Lauber C, Vieyres G, Terzyczyńska-Dyla E, Anggakusuma, Dijkman R, Gad HH et al. Transcriptome analysis reveals a classical interferon signature induced by IFNλ in human primary cells. Genes Immun 2015; 16: 414–421.

Egli A, Santer DM, O’Shea D, Thomas BS et al. Immunomodulatory function of interleukin 28B during primary infection with cytomegalovirus. J Infect Dis 2014; 210: 717–727.

Fernández-Ruiz M, Corrales I, Arias M, Campistol JM, Giménez E, Crespo J et al. Association between individual and combined SNPs in genes related to innate immunity and incidence of CMV infection in seropositive kidney transplant patients. Am J Transplant 2015; 15: 1323–1335.

Bravo D, Solano C, Giménez E, Remigia MJ, Corrales I, Artig P et al. Effect of the IL28B rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J Med Virol 2014; 86: 838–844.

Fernández-Ruiz M, Wojtowicz A, Taffé P, Manuel O, Bernasconi E, Furrer H et al. The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus reactivation among HIV-infected patients. AIDS 2014; 28: 1885–1899.

Manuel O, Wojtowicz A, Biberst N, Mueller NJ, van Delden C, Hirsch HH et al. Influence of IFN/Lambda3 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis 2015; 211: 906–914.

Treviño A, López M, Vispo E, Aquilera A, Ramos JM, Benito R. Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. Clin Infect Dis 2012; 54: e1–e4.

Assonne T, de Souza VF, Gaetzer KO, Fonseca LA, Luiz Odo C, Malta F et al. IL28B gene polymorphism SNP rs8099917 genotype GG is associated with HTLV-1 carriers. PLoS Negl Trop Dis 2012; 6: e1319.

Sanabani SS, Nukui Y, Pereira J, de Costa AC, de Oliveira AC, Pessoa R et al. Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load. BMC Infect Dis 2012; 12: 374.

Vallinoto AC, Santana BB, Sá KS, Ferreira TC, Sousa RC, Azvedo VN et al. HTLV-1: associated myelopathy/ tropical spastic paraparesis is not associated with SNP rs12979860 of the IL-28B gene. Mediators Inflamm 2015; 2015: 804167.

de Sá KS, Santana BB, de Souza Ferreira TC, Sousa RC, Caldas CA, Azvedo VN et al. IL28B gene polymorphisms and HLA-Th2 cytokine levels might be associated with HTLV-associated arthropathy. Cytokine 2016; 77: 79–87.

Kamihira S, Usui T, Ichikawa T, Ono N, Morinaga Y, Morisato T et al. Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus type-1 mono-infection and co-infection with hepatitis C virus. Viral J 2012; 9: 40.

Jeannin S, Costa JM, Poveda JD, Belrose G, Lezin A, Cabie A et al. Absence of association of IFNL3/IL28B rs12979860 and IFNL4 ss46941559 polymorphisms with the neurological status of HTLV-1-Afro-Caribbean subjects in Martinique. Retrovirology 2015; 12(Suppl 1): P61.

Leong CR, Oshiumi H, Suzuki T, Matsumoto M, Seya T. Nucleic acid sensors involved in the recognition of HBV in the liver-specific in vivo transfection mouse models-Pattern recognition receptors and sensors for HBV. Med Microbiol Immunol 2015; 204: 352.

Takahashi T. Interleukin 28B genetic polymorphism and hepatitis B virus infection. World J Gastroenterol 2014; 20: 12026–12030.

Velasco-Comandini U, Lapa D, Taba C, Angelotti C, Capobianchi MR, Garbuglia AR. No impact of interleukin-28B polymorphisms on spontaneous or drug induced hepatitis delta virus clearance. Dig Liver Dis 2014; 46: 348–352.

Yilmaz E, Baran B, Soyer OM, Onel M, Onel D, Ormeci AC et al. Effects of polymorphisms in interferon λ3 (interleukin 28B) on sustained virologic response to
therapy in patients with chronic hepatitis D virus infection. Clin Gastroenterol Hepatol 2014; 12: 1753–1758.

66 Sajadi MM, Shakiri N, Taliaros WA, Redfield RR. Hepatitis C infection in HIV-1 viral suppressors. AIDS 2010; 24: 1689–1695.

67 Ruiz-Mateos E, Machmack K, Romero-Sánchez MC, Ferrando-Martínez S, Viciana P, Del Val M et al. Hepatitis C virus replication in Caucasian HIV controllers. J Viral Hepat 2011; 18: e330–e357.

68 Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010; 202: 1749–1753.

69 Rallon NI, Restrepo C, Naggie S, Lopez M, Del Romero J, Goldstein D et al. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. AIDS 2011; 25: 269–271.

70 Salgado M, Kirk GD, Cox A, Ruttebarberwa A, Huggins Y, Astemborski J et al. Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors. AIDS 2011; 25: 385–387.

71 Sajadi MM, Shakiri N, Taliaros WA, Howell CD, Pakyz R, Redfield RR et al. IL28B genotype does not correlate with HIV control in African Americans. Clin Transl Sci 2011; 4: 282–284.

72 Machmack K, Abad-Molina C, Romero-Sánchez MC, Abad MA, Ferrando-Martínez S, Genebat M et al. IL28B single-nucleotide polymorphism rs12979860 is associated with spontaneous HIV control in white subjects. J Infect Dis 2013; 207: 651–655.

73 Machmack K, Abad-Molina C, Romero-Sánchez MC, Dominguez-Molina B, Moyano R, Rodriguez MM et al. IFNL4 ss46915590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals. Clin Microbiol Infect 2015; 21: e1–e4.

74 Real LM, Herrero R, Rivero-Juárez A, Camacho J, Viciana P, Del Romero J, Goldstein D et al. Interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology 2014; 59: 828–838.

75 Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ et al. Impaired induction of interleukin 28B and expression of interferon X4 associated with nonresponse to interferon-based therapy in chronic hepatitis C. J Gastroenterol Hepatol 2015; 30: 1075–1084.

76 Lang Kuhs KA, Kuniholm MH, Pfeiffer RM, Chen S, Desai S, Edlin BR et al. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant. J Viral Hepat 2014; 21: 397–404.

77 Honda M, Shirosaki T, Shimakami K, Saki A, Horii R, Araki K et al. Hepatic interferon-stimulated-genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology 2014; 59: 828–838.

78 Chinnaswamy S, Chandra V, Rampurkar V, Chandra V et al. Roles for transcription factors Sp1, NF-kB, IRF3, and IRF7 in expression of the human IFNL4 gene. Viral Immunol 2016; 29: 49–63.

79 Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semenov N et al. IL28B expression depends on a novel TFI/G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109–1116.

80 Sajadi MM, Supphai V, O’Connor K, Berg T, Weltman M, Abate ML et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C virus using massively parallel sequencing in a cross-sectional European cohort. Genome Med 2011; 3: 57.

81 Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. Interferon-X4 (IFNL4) transcript expression in human liver tissue samples. PLoS One 2013; 8: e84026.

82 Murakawa M, Asahina Y, Nakagawa M, Sakamoto N, Nitta S, Kusano-Kitazume A et al. IL-28B transcript expression in liver and expression of interferon X4 associated with nonresponse to interferon-based therapy in chronic hepatitis C. J Hepatol 2013; 58: 1045–1053.

83 Neter M, Rotman Y, Zhang F, Park H, Rehermann B, Thomas E et al. Hepatic expression levels of interferon and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study. Genes Immun 2015; 16: 321–329.

84 Konishi H, Motomura T, Matsumoto Y, Harimoto N, Ikegami T, Yoshizumi T et al. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant. J Viral Hepat 2014; 21: 397–404.

85 Malhotra S, Morcillo-Suárez C, Brassat D, Goertsches R, Lechner-Scott J, Urcelay E et al. Impact of IL-28B genetic polymorphisms on the response to interferon-α in multiple sclerosis. J Neuroimmunol 2014; 275: 167–171.